BERLIN 2025 ESMO congress

555MO

Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study

P. Schmid[1], H.C. Wang[2], F. Lynce[3], Y.H. Park[4], C.X. Ma[5], K.H. Jung[6], S.C. Chen[7], M-F. Hou[8], C. Prady[9], L-M. Tseng[10], J. Asselah[11], P.J. Wysocki[12], S. Lord[13], P. Rao-Melacini[14], R. Stewart[15], K. Warzyszynska[16], P. Vukovic[17], S-A. Im[18]

[1] Centre of Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom, [2] Department of Surgery, China Medical University Hospital, Taichung, Taiwan, [3] Department of Medical Oncology, Breast Oncology Program, Dana-Farber Cancer Institute and Harvard Medical School, Boston, United States of America, [4] Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, [5] Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, United States of America, [6] Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Republic of Korea, [7] Division of Breast Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan, [8] Division of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, [9] Oncology, Sherbrooke University, Centre Intégré de Cancérologie de la Montérégie, CISSS Montérégie Centre, Greenfield Park, Canada, [10] Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan, [11] Medical Oncology, McGill University Health Centre, Montreal, Canada, [12] Department of Oncology, Jagiellonian University Medical College, Krakow, Poland, [13] Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom, [14] Statistics, Oncology R&D, AstraZeneca Canada, Inc., Mississauga, Canada, [15] Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom, [16] Clinical Development, Oncology R&D, AstraZeneca, Warsaw, Poland, [17] Clinical Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom[18] Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea

Background

BEGONIA (NCT03742102) is a 2-part, open-label platform study evaluating the safety and efficacy of D, anti-PD-L1 antibody, combined with novel therapies as 1L tx for a/mTNBC. We report updated data for D in combination with Dato-DXd (a TROP2-directed antibody-drug conjugate) from arm 7 and the first report from arm 8.

Methods

Patients (pts) with unresectable a/mTNBC eligible for 1L tx were enrolled. Arm 7 included pts regardless of tumour PD-L1 expression level. Arm 8 enrolled pts with PD-L1-high tumours, as determined by IHC assay (local test). Pts received Dato-DXd 6 mg/kg IV + D 1120 mg IV Q3W until progression or unacceptable toxicity. Primary endpoints were safety and tolerability. Secondary endpoints included confirmed objective response rate (cORR) assessed by investigator, duration of response (DoR) and progression-free survival (PFS) per RECIST 1.1.

Results

At data cut-off (29 Nov 2024), 62 pts had received Dato-DXd + D (19.4% ongoing study tx) in arm 7 and 33 pts received Dato-DXd + D (45.4% ongoing study tx) in arm 8. In arm 7 (median follow-up 35.0 months), cORR was 79.0% (95% CI 66.8–88.3). Median DoR was 17.6 months (95% CI 10.5–27.3). Median PFS was 14.0 months (11.0–21.1). In arm 8 (median follow-up of 10.7 months), cORR was 81.8% (95% CI 64.5–93.0). Median DoR and median PFS could not be accurately determined due to the short follow up period. Safety data are summarised in the Table. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 3 (5%) pts in arm 7 (grade 2: n=2; grade 1: n=1) and 1 (3%) pt in arm 8 (grade 2).Table: 555MO

	Dato-DXd + D	
	Arm 7 (N=62)	Arm 8 (N=33)
Safety, n (%)		
Any AEs	62 (100)	33 (100)
Grade ¾	37 (60)	12 (36)
Most common AEs		
Stomatitis	43 (69)	27 (82)
Grade 3/4	10 (16.1)	0
Nausea	42 (68)	18 (55)

	Dato-DXd + D	
	Arm 7 (N=62)	Arm 8 (N=33)
Grade 3/4	0	0
TRAEs	62 (100)	33 (100)
Grade 3/4	30 (48)	8 (24)
Serious AEs	18 (29)	5 (15)
AEs leading to:		
Discontinuation of any study treatment	12 (19)	3 (9)
Death	1 (2)*	0
Immune-mediated AEs†	20 (32)	11 (33)
Grade 3/4	1 (1.6)	0

AEs, adverse events; TRAEs, treatment-related AE.*Not related to study tx.†Most common were hypothyroid events (Arm 7: 23%; Arm 8: 24%).

Conclusions

In 1L a/mTNBC, the combination of Dato-DXd + D continued to demonstrate robust antitumour activity across both arms. The safety profile was manageable with no new safety signals.

Clinical trial identification

NCT03742102; release date 15 November 2018.

Editorial acknowledgement

Medical writing support for the development of this abstract, under the direction of the authors, was provided by Lydia Hallam of Ashfield MedComms (London, UK), an Inizio company, and was funded by AstraZeneca.

Legal entity responsible for the study

AstraZeneca.

Funding

This trial is sponsored by AstraZeneca. In July 2020, Daiichi Sankyo entered into a global development and commercialisation collaboration with AstraZeneca for datopotamab deruxtecan (Dato-DXd).

Disclosure

P. Schmid: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Pfizer, Roche, Gilead, Daiichi Sankyo, MSD, Bicycle Therapeutics, Lilly, Summit Therapeutics, Olema Oncology; Financial Interests, Personal, Invited Speaker: Menarini-Stemline, Gilead, AstraZeneca, Daiichi Sankyo, MSD, Roche; Financial Interests, Institutional, Research Grant: AstraZeneca, Genentech, Roche. F. Lynce: Financial Interests, Personal, Advisory Role, Consulting: AstraZeneca, Pfizer, Eli-Lilly, Daiichi Sankyo; Financial Interests, Institutional, Research Funding: Merck, AstraZeneca, Zentalis, Ideaya, and Gilead. Y.H. Park: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Lilly, MSD, Roche, Daiichi Sankyo, Gilead, Helsinn, Novartis; Financial Interests, Personal, Advisory Role: AstraZeneca, Pfizer, Lilly, MSD, Roche, Daiichi Sankyo, Gilead, Helsinn, Novartis, Inocras, Voronoi; Non-Financial Interests, Personal, Coordinating PI: AstraZeneca; Financial Interests, Personal, Funding: AstraZeneca, MSD, Roche, Daewoong, Gilead, Novartis ; Financial Interests, Personal, Research Funding: AstraZeneca, Pfizer, Lilly, MSD, Roche, Daiichi Sankyo, Gilead, Helsinn, Novartis; Non-Financial Interests, Personal, Principal Investigator: AstraZeneca, Pfizer, Lilly, MSD, Roche, Daiichi Sankyo, Gilead, Novartis, Menarini; Financial Interests, Personal, Research Grant: Novartis, AstraZeneca, Pizer, Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Pfizer, Lilly, MSD, Roche, Daiichi Sankyo, Gilead, Novartis, Menarini; Financial Interests, Personal, Steering Committee Member: AstraZeneca, MSD, Roche, Daiichi Sankyo, Gilead, Jazz Pharmaceuticals; Non-Financial Interests, Personal, Writing Engagement: Pfizer, Roche, AstraZeneca, Novartis, Daiichi Sankyo, Gilead. C.X. Ma: Financial Interests, Personal, Advisory Role, Consulting: Athenex, AstraZeneca, Daiichi Sankyo, Danatlas, Seattle Genetics, Sermonix; Financial Interests, Personal, Advisory Board: Bayer HealthCare, Biovica, Eli Lilly, Gilead Sciences, Inivata, Jacobio, Merck Sharp & Dohme Corp., Novartis, RayzoBio, Sanofi; Financial Interests, Personal, Advisory Role, Consulting / Advisory Board: Eisai, Natera, Olaris, Oncosignal, Pfizer , Philips Electronics; Financial Interests, Personal, Invited Speaker, Honoraria for speaking/lectures: Guardant Health; Financial Interests, Personal, Invited Speaker, Speaking Fees/Honoraria: Mount Sinai School of Medicine, PlusOne Health GmbH; Financial Interests, Personal, Speaker, Consultant, Advisor, Fees for lecture: OncLive; Financial Interests, Personal, Other, Clinical Trial Funding, pre clinical studies, Consultant/Advisory Board: Puma; Financial Interests, Personal, Advisory Board, Tempus Sequencing & Advisory Board: Tempus; Non-Financial Interests, Personal, Writing Engagement, Article Reviewer: The Lancet Oncology; Non-Financial

Interests, Personal, Writing Engagement, Services for non-US entities - Scientific reviews or evaluation panels: The Ohio State University; Non-Financial Interests, Personal, Writing Engagement, Authorship/Article Publication: UpToDate. K.H. Jung: Financial Interests, Personal, Advisory Role: AstraZeneca, Daiichi Sankyo, Gilead Science, Novartis, Roche, Eisai, Pfizer, MSD. C. Prady: Financial Interests, Institutional, Research Funding: AstraZeneca, Sanofi, Roche, Novartis; Financial Interests, Institutional, Other, Clinical trial activity: AstraZeneca, Sanofi, Roche, Novartis. J. Asselah: Financial Interests, Personal, Invited Speaker: AstraZeneca, Pfizer, Eisai, Novartis, BMS; Financial Interests, Advisory Role, Consulting: AstraZeneca, Pfizer, Eisai, Novartis, BMS. P.J. Wysocki: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Principal Investigator: AstraZeneca. S. Lord: Financial Interests, Institutional, Local PI: AstraZeneca. P. Rao-Melacini: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. R. Stewart: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. K. Warzyszynska: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Sponsor/Funding: AstraZeneca. P. Vukovic: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. S. Im: Financial Interests, Personal, Advisory Board, no payment: AstraZeneca, Novartis, Eisai, Roche, Pfizer, Lilly, MSD, GSK, Daiichi Sankyo; Financial Interests, Institutional, Research Grant: AstraZeneca, Pfizer, Roche, Eisai; Financial Interests, Institutional, Local PI, Clinical Trial Budget: AstraZeneca, Novartis, Roche, Pfizer, Daiichi Sankyo, MSD, Lilly; Financial Interests, Institutional, Coordinating PI, Clinical Trial Budget: Eisai; Financial Interests, Institutional, Research Grant, Clinical Trial Budget: Boryung Pharm. All other authors have declared no conflicts of interest.